RGNX
Biotechnology · Healthcare
COO, Board Member
2024-01-01–present
Board Member
REGENXBIO Inc. (RGNX)Equibles does not estimate personal net worth.
Get an email with a short summary when REGENXBIO Inc. publishes a filing, an earnings call transcript or a press release.
Get RGNX alertsCurran Simpson is recorded as Board Member at REGENXBIO Inc. (RGNX) since January 1, 2024 and COO at REGENXBIO Inc. (RGNX). The newest filing on record that lists Curran Simpson as Board Member at REGENXBIO Inc. (RGNX) is dated April 14, 2026. The proxy statement of REGENXBIO Inc. reports total compensation of $4,200,712 for Curran Simpson in fiscal 2025, including a base salary of $665,510. Disclosed compensation is on record for 8 fiscal years. Curran Simpson has spoken on 9 earnings calls and 3 other investor events across 1 company, most recently for REGENXBIO Inc. on November 5, 2026. REGENXBIO Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at REGENXBIO Inc. includes Curran M. Simpson (CEO, COO and Board Member), Allan M. Fox (Chairman and Board Member), George Migausky (Chairman and Board Member) and 7 others.
“This is an exciting time for RegenexBio. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pecola, our Chief Medical Officer, and Mitch Chan, our Chief Financial Officer.”
“We've been in AAV gene therapy for 15 plus years at this point.”
“We've been in AAV gene therapy for 15 plus years at this point.”
“The second quarter was another period of positive momentum for RegenexBio, achieving key milestones across our late-stage pipeline of gene therapies.”
“Yeah, I actually would probably want to clarify the weighting aspect of that is further discussions with FDA. So what we're looking to do is see FDA stabilize in terms of new leadership, additional changes last week, as everybody saw.”
2024-01-01–present
Last confirmed April 14, 2026
RGNX
Biotechnology · Healthcare
COO, Board Member
2024-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | REGENXBIO Inc. (RGNX) | President and Chief Executive Officer | $665,510 | $4,200,712 |
| 2024 | REGENXBIO Inc. (RGNX) | President and CEO | $571,723 | $4,784,543 |
| 2023 | REGENXBIO Inc. (RGNX) | President and CEO | $512,928 | $2,950,002 |
| 2022 | REGENXBIO Inc. (RGNX) | President and CEO | $474,933 | $2,097,463 |
| 2021 | REGENXBIO Inc. (RGNX) | EVP, Chief Operating Officer | $448,050 | $3,247,167 |
| 2020 | REGENXBIO Inc. (RGNX) | EVP, Chief Operating Officer | $428,152 | $1,750,865 |
| 2019 | REGENXBIO Inc. (RGNX) | EVP, Chief Operations and Technology Officer | $382,439 | $1,825,744 |
| 2018 | REGENXBIO Inc. (RGNX) | Senior Vice President, Chief Operations and Technology Officer | $371,300 | $1,901,142 |